Listed

Ensysce Biosciences, Inc.

ENSCNasdaqCIK 1716947HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.2m, Q2 FY2026
Operating income−$2.6m, Q2 FY2026
Net income−$2.6m, Q2 FY2026
Ensysce Biosciences, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k435Revenue, Q3 FY2023, three months to 2023-09-30$435.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure515Revenue, Q4 FY2023, three months to 2023-12-31$515.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-10, accession 0001493152-25-009703. Derived: 12-month figure less the 9-month figure.Report this figure306Revenue, Q1 FY2024, three months to 2024-03-31$305.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure182Revenue, Q2 FY2024, three months to 2024-06-30$181.8k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure3,419Revenue, Q3 FY2024, three months to 2024-09-30$3.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure1,304Revenue, Q4 FY2024, three months to 2024-12-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure1,320Revenue, Q1 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure1,371Revenue, Q2 FY2025, three months to 2025-06-30$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure493Revenue, Q3 FY2025, three months to 2025-09-30$493.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure1,882Revenue, Q4 FY2025, three months to 2025-12-31$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure961Revenue, Q1 FY2026, three months to 2026-03-31$961.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure1,164Revenue, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Research and development$k1,915Research and development, Q3 FY2023, three months to 2023-09-30$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure2,233Research and development, Q4 FY2023, three months to 2023-12-31$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-10, accession 0001493152-25-009703. Derived: 12-month figure less the 9-month figure.Report this figure779Research and development, Q1 FY2024, three months to 2024-03-31$778.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure947Research and development, Q2 FY2024, three months to 2024-06-30$947.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure1,691Research and development, Q3 FY2024, three months to 2024-09-30$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure3,803Research and development, Q4 FY2024, three months to 2024-12-31$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure1,886Research and development, Q1 FY2025, three months to 2025-03-31$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure1,923Research and development, Q2 FY2025, three months to 2025-06-30$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure2,955Research and development, Q3 FY2025, three months to 2025-09-30$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure3,613Research and development, Q4 FY2025, three months to 2025-12-31$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure3,347Research and development, Q1 FY2026, three months to 2026-03-31$3.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure2,472Research and development, Q2 FY2026, three months to 2026-06-30$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Selling, general and administrative$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$k(2,707)Operating income, Q3 FY2023, three months to 2023-09-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure(3,156)Operating income, Q4 FY2023, three months to 2023-12-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-10, accession 0001493152-25-009703. Derived: 12-month figure less the 9-month figure.Report this figure(1,843)Operating income, Q1 FY2024, three months to 2024-03-31−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure(1,955)Operating income, Q2 FY2024, three months to 2024-06-30−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure645Operating income, Q3 FY2024, three months to 2024-09-30$644.7k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure(3,576)Operating income, Q4 FY2024, three months to 2024-12-31−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure(1,968)Operating income, Q1 FY2025, three months to 2025-03-31−$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(1,751)Operating income, Q2 FY2025, three months to 2025-06-30−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure(3,741)Operating income, Q3 FY2025, three months to 2025-09-30−$3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure(2,782)Operating income, Q4 FY2025, three months to 2025-12-31−$2.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure(3,562)Operating income, Q1 FY2026, three months to 2026-03-31−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(2,576)Operating income, Q2 FY2026, three months to 2026-06-30−$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Interest expense$k7.6Interest expense, Q3 FY2023, three months to 2023-09-30$7.6k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure345Interest expense, Q4 FY2023, three months to 2023-12-31$344.8k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-15, accession 0001493152-24-009993. Derived: 12-month figure less the 9-month figure.Report this figure1,248Interest expense, Q1 FY2024, three months to 2024-03-31$1.2m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure27.6Interest expense, Q2 FY2024, three months to 2024-06-30$27.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure4.1Interest expense, Q3 FY2024, three months to 2024-09-30$4.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure10.8Interest expense, Q4 FY2024, three months to 2024-12-31$10.8k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure3.9Interest expense, Q1 FY2025, three months to 2025-03-31$3.9k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure3.2Interest expense, Q2 FY2025, three months to 2025-06-30$3.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure6.4Interest expense, Q3 FY2025, three months to 2025-09-30$6.4k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure5.4Interest expense, Q4 FY2025, three months to 2025-12-31$5.4k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure3.9Interest expense, Q1 FY2026, three months to 2026-03-31$3.9k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure0.3Interest expense, Q2 FY2026, three months to 2026-06-30$320. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(2,691)Net income, Q3 FY2023, three months to 2023-09-30−$2.7m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure(3,504)Net income, Q4 FY2023, three months to 2023-12-31−$3.5m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2025-03-10, accession 0001493152-25-009703. Derived: 12-month figure less the 9-month figure.Report this figure(3,117)Net income, Q1 FY2024, three months to 2024-03-31−$3.1m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure(1,968)Net income, Q2 FY2024, three months to 2024-06-30−$2.0m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure662Net income, Q3 FY2024, three months to 2024-09-30$661.8k. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure(3,564)Net income, Q4 FY2024, three months to 2024-12-31−$3.6m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure(1,946)Net income, Q1 FY2025, three months to 2025-03-31−$1.9m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(1,734)Net income, Q2 FY2025, three months to 2025-06-30−$1.7m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure(3,729)Net income, Q3 FY2025, three months to 2025-09-30−$3.7m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure(2,768)Net income, Q4 FY2025, three months to 2025-12-31−$2.8m. XBRL concept us-gaap:ProfitLoss. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure(3,556)Net income, Q1 FY2026, three months to 2026-03-31−$3.6m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(2,571)Net income, Q2 FY2026, three months to 2026-06-30−$2.6m. XBRL concept us-gaap:ProfitLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Diluted EPS$ per share(0.87)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figurenot reported(8.21)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$8.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure(3.35)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$3.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure1.00Diluted EPS, Q3 FY2024, three months to 2024-09-30$1.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figurenot reported(1.39)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(0.79)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure(1.29)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figurenot reported(0.52)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(0.20)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Basic EPS$ per share(0.87)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figurenot reported(8.21)Basic EPS, Q1 FY2024, three months to 2024-03-31−$8.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure(3.35)Basic EPS, Q2 FY2024, three months to 2024-06-30−$3.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure1.00Basic EPS, Q3 FY2024, three months to 2024-09-30$1.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figurenot reported(1.39)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(0.79)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.79 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure(1.29)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figurenot reported(0.52)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(0.20)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure

Balance sheet

Cash and equivalents$676.7k, Q2 FY2026
Shareholders' equity−$781.7k, Q2 FY2026
Ensysce Biosciences, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$k1,464Cash and equivalents, Q3 FY2023, at 2023-09-30$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure1,124Cash and equivalents, FY2023, at 2023-12-31$1.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-10, accession 0001493152-25-009703.Report this figure3,404Cash and equivalents, Q1 FY2024, at 2024-03-31$3.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure1,043Cash and equivalents, Q2 FY2024, at 2024-06-30$1.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure4,154Cash and equivalents, Q3 FY2024, at 2024-09-30$4.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure3,502Cash and equivalents, FY2024, at 2024-12-31$3.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001493152-26-013633.Report this figure3,052Cash and equivalents, Q1 FY2025, at 2025-03-31$3.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure2,212Cash and equivalents, Q2 FY2025, at 2025-06-30$2.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure1,673Cash and equivalents, Q3 FY2025, at 2025-09-30$1.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure4,310Cash and equivalents, FY2025, at 2025-12-31$4.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure745Cash and equivalents, Q1 FY2026, at 2026-03-31$745.5k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure677Cash and equivalents, Q2 FY2026, at 2026-06-30$676.7k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Current assets$k2,758Current assets, Q3 FY2023, at 2023-09-30$2.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure2,289Current assets, FY2023, at 2023-12-31$2.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-10, accession 0001493152-25-009703.Report this figure4,697Current assets, Q1 FY2024, at 2024-03-31$4.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure2,460Current assets, Q2 FY2024, at 2024-06-30$2.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure9,091Current assets, Q3 FY2024, at 2024-09-30$9.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure5,345Current assets, FY2024, at 2024-12-31$5.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001493152-26-013633.Report this figure4,401Current assets, Q1 FY2025, at 2025-03-31$4.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure5,282Current assets, Q2 FY2025, at 2025-06-30$5.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure2,928Current assets, Q3 FY2025, at 2025-09-30$2.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure7,245Current assets, FY2025, at 2025-12-31$7.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure2,009Current assets, Q1 FY2026, at 2026-03-31$2.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure2,846Current assets, Q2 FY2026, at 2026-06-30$2.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Total assets$k3,219Total assets, Q3 FY2023, at 2023-09-30$3.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure2,708Total assets, FY2023, at 2023-12-31$2.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-10, accession 0001493152-25-009703.Report this figure5,074Total assets, Q1 FY2024, at 2024-03-31$5.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure2,796Total assets, Q2 FY2024, at 2024-06-30$2.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure9,385Total assets, Q3 FY2024, at 2024-09-30$9.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure5,597Total assets, FY2024, at 2024-12-31$5.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001493152-26-013633.Report this figure4,612Total assets, Q1 FY2025, at 2025-03-31$4.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure5,574Total assets, Q2 FY2025, at 2025-06-30$5.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure3,179Total assets, Q3 FY2025, at 2025-09-30$3.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure7,452Total assets, FY2025, at 2025-12-31$7.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure2,168Total assets, Q1 FY2026, at 2026-03-31$2.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure2,957Total assets, Q2 FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Current liabilities$k2,031Current liabilities, Q3 FY2023, at 2023-09-30$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure3,333Current liabilities, FY2023, at 2023-12-31$3.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-10, accession 0001493152-25-009703.Report this figure1,636Current liabilities, Q1 FY2024, at 2024-03-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure1,307Current liabilities, Q2 FY2024, at 2024-06-30$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure2,802Current liabilities, Q3 FY2024, at 2024-09-30$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure2,207Current liabilities, FY2024, at 2024-12-31$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001493152-26-013633.Report this figure1,761Current liabilities, Q1 FY2025, at 2025-03-31$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure2,513Current liabilities, Q2 FY2025, at 2025-06-30$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure2,305Current liabilities, Q3 FY2025, at 2025-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure4,568Current liabilities, FY2025, at 2025-12-31$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure2,837Current liabilities, Q1 FY2026, at 2026-03-31$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure4,068Current liabilities, Q2 FY2026, at 2026-06-30$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Total liabilities$k2,061Total liabilities, Q3 FY2023, at 2023-09-30$2.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure3,359Total liabilities, FY2023, at 2023-12-31$3.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-10, accession 0001493152-25-009703.Report this figure1,654Total liabilities, Q1 FY2024, at 2024-03-31$1.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure1,316Total liabilities, Q2 FY2024, at 2024-06-30$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure2,805Total liabilities, Q3 FY2024, at 2024-09-30$2.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure2,217Total liabilities, FY2024, at 2024-12-31$2.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001493152-26-013633.Report this figure1,891Total liabilities, Q1 FY2025, at 2025-03-31$1.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure2,514Total liabilities, Q2 FY2025, at 2025-06-30$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure2,305Total liabilities, Q3 FY2025, at 2025-09-30$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure4,568Total liabilities, FY2025, at 2025-12-31$4.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure2,837Total liabilities, Q1 FY2026, at 2026-03-31$2.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure4,068Total liabilities, Q2 FY2026, at 2026-06-30$4.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure
Shareholders' equity$k1,485Shareholders' equity, Q3 FY2023, at 2023-09-30$1.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure(323)Shareholders' equity, FY2023, at 2023-12-31−$322.9k. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-03-10, accession 0001493152-25-009703.Report this figure3,749Shareholders' equity, Q1 FY2024, at 2024-03-31$3.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure1,808Shareholders' equity, Q2 FY2024, at 2024-06-30$1.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure6,908Shareholders' equity, Q3 FY2024, at 2024-09-30$6.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure3,708Shareholders' equity, FY2024, at 2024-12-31$3.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001493152-26-013633.Report this figure3,049Shareholders' equity, Q1 FY2025, at 2025-03-31$3.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure3,389Shareholders' equity, Q2 FY2025, at 2025-06-30$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure1,203Shareholders' equity, Q3 FY2025, at 2025-09-30$1.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure3,214Shareholders' equity, FY2025, at 2025-12-31$3.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure(340)Shareholders' equity, Q1 FY2026, at 2026-03-31−$340.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(782)Shareholders' equity, Q2 FY2026, at 2026-06-30−$781.7k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure

Cash flow

Operating cash flow−$2.0m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Ensysce Biosciences, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(2,263)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001493152-24-044768. Derived: 9-month figure less the 6-month figure.Report this figure(1,802)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-10, accession 0001493152-25-009703. Derived: 12-month figure less the 9-month figure.Report this figure(3,408)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure(2,310)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001641172-25-023512. Derived: 6-month figure less the 3-month figure.Report this figure(1,020)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023498. Derived: 9-month figure less the 6-month figure.Report this figure(764)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$764.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure(1,707)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(2,707)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$2.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037817. Derived: 6-month figure less the 3-month figure.Report this figure(1,866)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023498. Derived: 9-month figure less the 6-month figure.Report this figure(1,526)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figure(3,501)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure(1,962)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037817. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001493152-26-013633. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Share repurchases$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)13.04m, Q2 FY2026
Ensysce Biosciences, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30160,719 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001493152-23-040091.Report this figure1.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-311,054,202 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-13, accession 0001493152-24-018718.Report this figure2.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-302,274,113 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001493152-24-032263.Report this figure3.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-303,085,873 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001493152-24-044768.Report this figure0.4Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31379,634 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001641172-25-009955.Report this figure0.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30587,822 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001641172-25-023512.Report this figure0.7Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30659,361 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure1.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,401,144 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure2.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-302,202,299 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure2.9Diluted shares (weighted), Q3 FY2025, three months to 2025-09-302,886,059 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001493152-25-023498.Report this figure6.8Diluted shares (weighted), Q1 FY2026, three months to 2026-03-316,839,385 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001493152-26-023811.Report this figure13.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3013,035,632 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure

Shares outstanding: 19.46mShares outstanding, period not labelled, at 2026-08-1219,456,794 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037817.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.